ALK-Abelló Logo

ALK-Abelló

Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.

ALK | CO

Overview

Corporate Details

ISIN(s):
DK0061802139
LEI:
529900SGCREUZCZ7P020
Country:
Denmark
Address:
Bøge Alle 6-8, 2970 Hørsholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ALK-Abelló is a global pharmaceutical company specializing in the research, development, and manufacturing of allergy immunotherapy (AIT) products. A pioneer in the field for over a century, the company focuses on creating treatments that address the underlying cause of allergies, rather than merely managing symptoms. Its portfolio encompasses a range of evidence-based AIT products, including tablets, drops, and injections, as well as emergency treatments for severe allergic reactions like anaphylaxis. ALK's primary therapeutic areas are respiratory allergies, food allergies, and anaphylaxis. The company is committed to scientific innovation and expanding access to its solutions, such as needle-free adrenaline treatments, to improve the lives of people with allergies worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-17 09:44
M&A Activity
Danish 174.5 KB
2025-09-17 09:44
M&A Activity
Danish 10.0 KB
2025-09-17 09:44
M&A Activity
English 8.9 KB
2025-09-17 09:44
M&A Activity
English 274.6 KB
2025-08-21 07:30
Earnings Release
English 11.5 KB
2025-08-21 07:30
Interim Report
English 505.8 KB
2025-08-21 07:30
Interim Report
English 505.8 KB
2025-08-21 07:30
Earnings Release
English 12.0 KB
2025-08-12 14:45
Earnings Release
Danish 103.0 KB
2025-08-12 14:45
Earnings Release
Danish 3.7 KB
2025-08-12 14:45
Earnings Release
English 108.6 KB
2025-08-12 14:45
Earnings Release
English 3.2 KB
2025-07-18 14:01
Regulatory News Service
Danish 174.9 KB
2025-07-18 14:01
Legal Proceedings Report
English 5.2 KB
2025-07-18 14:01
Regulatory News Service
Danish 5.3 KB

Automate Your Workflow. Get a real-time feed of all ALK-Abelló filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ALK-Abelló via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Biofarm S.A. Logo
A top domestic manufacturer of pharmaceuticals, supplements, and soft gelatin capsules.
Romania BIO
Biofrontera AG Logo
Biopharma firm specializing in photodynamic therapy for dermatological conditions like actinic keratosis.
Germany B8F
BioGaia Logo
Develops and commercializes clinically proven probiotics for digestive health across all life stages.
Sweden BIOG
Bio-Gate AG Logo
Develops antimicrobial & antiviral tech for medical, cosmetic, & industrial products.
Germany BIG1
BioInfra Co.,Ltd. Logo
Offers cancer screening blood tests and provides CRO services to the pharmaceutical industry.
South Korea 199730
BioInfra Life Science Inc. Logo
Biotech specializing in oncology diagnostics and R&D for cancer gene treatments.
South Korea 266470
BioInvent International Logo
Develops first-in-class immuno-modulatory antibodies for cancer therapy.
Sweden BINV
BioLineRx Ltd. Logo
Biopharma firm developing and commercializing therapies for cancer and rare diseases.
Israel BLRX
BioMaxima S.A. Logo
Manufacturer of IVD solutions including tests, reagents, and equipment for medical labs.
Poland BMX
bioMérieux Logo
Provides in vitro diagnostic solutions for clinical and industrial microbiology.
France BIM

Talk to a Data Expert

Have a question? We'll get back to you promptly.